Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mogroside III-A2 exhibits inhibitory effects with IC50 values of 346-400 mol ratio/32 pmol TPA. and shows weak inhibitory effects on activation of (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 3,420 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 5,220 | 待询 |
产品描述 | Mogroside III-A2 exhibits inhibitory effects with IC50 values of 346-400 mol ratio/32 pmol TPA. and shows weak inhibitory effects on activation of (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor. |
体外活性 | Six new cucurbitane glycosides, mogroside II B (2), 11-deoxymogroside III (4), 7-oxomogroside II E (5), 7-oxomogroside V (6), 11-oxomogroside II A1 (7), and 11-oxomogroside IV A (8), and two known but new naturally occurring cucurbitane glycosides, mogroside II-A1 (1) and Mogroside III-A2 (3), were isolated from an ethanol extract of the fruits of Siraitia grosvenorii. |
别名 | Mogroside III-A2, 罗汉果苷IIIA2, 罗汉果苷 III A2 |
分子量 | 963.165 |
分子式 | C48H82O19 |
CAS No. | 88901-43-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mogroside III A2 88901-43-3 Others Mogroside III-A2 Mogroside III A-2 罗汉果苷IIIA2 罗汉果苷 III A2 Inhibitor inhibitor inhibit